PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. - Wikidata - awgldk - TriplyDB

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

http://www.wikidata.org/entity/Q35610581

about

Circulating DNA as biomarker in breast cancer Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Going beyond genetics to discover cancer targets Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.Drugging PI3K in cancer: refining targets and therapeutic strategies Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Mover's Distance.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Molecules in medicine mini-review: isoforms of PI3K in biology and disease.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Expression of Tim4 in Glioma and its Regulatory Role in LN-18 Glioma Cells.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Two is better than one; toward a rational design of combinatorial therapy.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.The MYCN Protein in Health and Disease.A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor α-positive breast cancer cells LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.The PI3K Pathway in Human Disease.PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma.Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.PI3K inhibition to overcome endocrine resistance in breast cancer.

P2860

Q26785343-E3A92E8E-2CEF-4AFA-88AF-24F11C6A46FA Q29248893-51D61130-0AD4-40B0-8F47-1958EA892869 Q33571040-80699D77-8B19-42AF-BC11-84B4A520A0B4 Q33711702-20E26696-9EE3-47A5-9071-C0167D466374 Q33776641-BBC0F223-6460-4B55-84DA-FDF9879ED29B Q34554022-D64E9851-84B5-493A-8F01-E4F5BF9773E4 Q36355880-4C7A4D8F-32C9-4C4B-9CE2-EC0F649DAC17 Q36450456-649671C5-F063-42AB-987C-ABEB195599C5 Q36849266-1B4E8C22-79F8-4862-B8B7-DDC9C72BB8AC Q37017948-839DD698-10D4-458B-A1E5-A289DA0E2190 Q37033301-EB0AA5D3-31F6-4638-BC5C-AE80466739A7 Q37107598-C031A657-E098-4E7A-996E-DFA83DFC6712 Q37696147-6C630E33-268C-4799-B808-DC52266D0F67 Q37708928-E98D0D29-1373-437D-A029-82FC757A3F52 Q38539217-4692B844-ED94-427E-B1C2-A234F68743D3 Q38602947-95758A60-2B6A-446A-86E0-1B9D48207F5B Q38647901-DDC23425-1DF8-47FF-95D4-A72BC99A765B Q38656763-1FCB20D6-5E39-4CD4-A962-53FE35E49209 Q38666875-A3A251FC-793B-460D-AFA5-407BD9BB6A80 Q38752466-1E3978EB-F11B-4B15-A991-5126F7FFD4CD Q38805940-E27603A6-BB02-4864-90D0-423BF24F056C Q38850598-193377F9-1EEC-40BA-884C-55CAB406EA7A Q38885290-992438E9-3D4C-4E28-A810-94AFF57B6A5F Q38926952-9885262C-66E8-43FA-9E66-BE6B8E3A6318 Q38933237-72492CDE-B72A-4EAA-8DF7-46402C6944B0 Q39023175-A74D1B13-1857-401C-9100-7C79E80F8318 Q39093601-08FEAFE0-C122-4AB6-B878-76087862B811 Q39208675-EE3717D1-860C-4638-83E4-461AC05E5DE5 Q40417182-9B85BEE0-0A7A-4599-BB0C-2DED498555EC Q40475630-B6E3250A-5B3E-4110-98F6-C25091716FF4 Q40591054-B5123CC2-E689-4EDD-B4C3-D46877E5D12A Q41672004-2AEE647E-A7E6-4E2C-A9F5-7641B288B25E Q42282812-BE97BD2C-E684-4AA0-BCED-0C42C1349763 Q46311036-4F28E96C-8A8A-412D-B711-E6CA581AA5EE Q46546002-3C7CC732-2FF9-4D52-B0DA-A01B09EA8097 Q46614822-F3AC73D7-37DB-4F65-B4A6-9693B78A1706 Q47202432-70705DDB-DEEC-421F-88E3-7D41E8733DBB Q47412586-B6A9AF14-7BBE-449F-B740-885FC323CBA0 Q47584016-BD5F7423-71A7-439E-BF65-0581B822B8BE Q47776273-21F5103B-DE0A-4227-B400-743CC1B6BA8E

P2860

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

http://www.wikidata.org/entity/Q35610581

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@ast

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@en

type

label

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@ast

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@en

prefLabel

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@ast

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@en

P1433

Q35610581-D804D3A2-F8D6-4B41-A0D5-0EC17C62CE4E

P1476

Q35610581-4BC599F6-E488-43BD-A756-606537BDD581

P2093

Q35610581-21A0EBDA-1CB7-432A-AF27-06F7282B5054

Q35610581-27A50A14-B184-4D4E-8C3D-4707785DE30F

Q35610581-3039CB6A-BB0C-43A9-94DA-1EEDC216F2C8

Q35610581-339A0AF2-A221-4B6B-9A67-206D37CD6689

Q35610581-3654827E-1D88-40BA-A8BC-A2F9F68688B1

Q35610581-39BC0080-0E1A-4B99-9EB5-B2D69007AF1D

Q35610581-697D8D44-07D7-480B-A901-051ACA64980B

Q35610581-75E87C32-9D0F-4A16-9533-4582F87E02EE

Q35610581-77B45AA9-D55D-4C3E-A142-703EE4F49334

Q35610581-77E05AF2-C6B8-435B-9009-1AB4A3F60990

P2860

Q35610581-0682CDAE-64A6-4E6C-BF9F-62A60A63F388

Q35610581-1024DC04-B627-498D-A97F-1B34A5E3B0D2

Q35610581-186AAE0A-B915-4A08-8E29-63B8FD6DDA38

Q35610581-1D9A7C76-F96B-4210-9F41-C0A6A70E028E

Q35610581-2C742643-1090-4DD4-8829-D3E1B6CF17B0

Q35610581-2EAAF559-E002-496F-9065-E2B2822CDE72

Q35610581-2EE7B94C-D723-4690-A9F2-C8EDF6FBBA6D

Q35610581-3C28B0D7-EBC1-47F3-8B25-327CC1B5133A

Q35610581-5191D167-4FCE-4308-A57F-0E95AF6B309F

Q35610581-525CACA4-301F-4D5C-B4C5-0F5DD3DE46DA

P304

Q35610581-0C865C99-BF0C-4871-B32C-7E7DB0123232

P31

Q35610581-3A67EAB1-DAC5-47A4-8937-50DA1340AD2B

P356

Q35610581-7567A370-4B48-4DEA-8BC8-52E786CCD461

P407

Q35610581-D78EEDB4-B8D1-4226-8788-38EFF017F106

P433

Q35610581-3C72735B-CFDC-4DD7-997A-358F9B9702C3

P478

Q35610581-824B9F46-A612-4121-A9B1-0B2945DF15B2

P50

Q35610581-0FFA25EC-B23A-4A59-BC38-3752DC80ED8E

Q35610581-20FF06A8-F227-4DA7-ABF8-3ABBC372BF53

Q35610581-399FA555-1FD5-4D02-88F2-5FB6C340E1C5

Q35610581-47183FA1-9250-4F51-8FE3-3E9BA5208B17

Q35610581-AB883A2E-A057-46AC-A7AB-9783B3F37093

Q35610581-B5538CD6-C35E-4C5E-8A2E-19A716F9A92E

Q35610581-B9DEDADA-9726-4662-90F9-157219878048

Q35610581-FAA89F9E-D276-4BA3-8C47-641CFE9D2F04

P577

Q35610581-C41142C3-CB21-41A1-A5C7-1ED9133BA986

P5875

Q35610581-531763C4-0272-401C-90FA-CE6365596CA6

P698

Q35610581-E4F46BA1-67AB-49A1-8C40-E5EE914E302E

P932

Q35610581-DC246171-F4C5-4920-946A-9C81DD5DBA4C

P356

SCITRANSLMED.AAA4442

P1433

Science Translational Medicine

P1476

PI3K inhibition results in enh ...... ceptor-positive breast cancer.

@en

P2093

Ana Bosch

http://www.w3.org/2001/XMLSchema#string

Anna Bergamaschi

http://www.w3.org/2001/XMLSchema#string

Eneda Toska

http://www.w3.org/2001/XMLSchema#string

Gerard Minuesa

http://www.w3.org/2001/XMLSchema#string

Haley Ellis

http://www.w3.org/2001/XMLSchema#string

Jason S Lewis

http://www.w3.org/2001/XMLSchema#string

Jessica J Tao

http://www.w3.org/2001/XMLSchema#string

John A Katzenellenbogen

http://www.w3.org/2001/XMLSchema#string

Jordi Rodón

http://www.w3.org/2001/XMLSchema#string

Jose Perez-Garcia

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Significance analysis of microarrays applied to the ionizing radiation response

Comprehensive molecular portraits of human breast tumours

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Gene expression profiling predicts clinical outcome of breast cancer

The phosphoinositide 3-kinase pathway

High frequency of mutations of the PIK3CA gene in human cancers

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

P304

283ra51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAA4442

http://www.w3.org/2001/XMLSchema#string

P407

P433

283

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Daniel E. Spratt

Michael G Kharas

Nerissa Therese Viola-Villegas

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276277714

http://www.w3.org/2001/XMLSchema#string

P698

25877889

http://www.w3.org/2001/XMLSchema#string

P932

4433148

http://www.w3.org/2001/XMLSchema#string